The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use
Abstract
Study Objectives. To review the labels of United States Food and Drug Administration (FDA)‐approved drugs to identify those that contain pharmacogenomic biomarker information, and to collect prevalence information on the use of those drugs for which pharmacogenomic information is included in the drug labeling. Design. Retrospective analysis. Data Sources. The Physicians' Desk Reference Web site, Drugs@FDA Web site, and manufacturers' Web sites were used to identify drug labels containing pharmacogenomic information, and the prescription claims database of a large pharmacy benefits manager (insuring > 55 million individuals in the United States) was used to obtain drug utilization data. Measurements and Main Results. Pharmacogenomic biomarkers were defined, FDA‐approved drug labels containing this information were identified, and utilization of these drugs was determined. Of 1200 drug labels reviewed for the years 1945–2005, 121 drug labels contained pharmacogenomic information based on a key word search and follow‐up screening. Of those, 69 labels referred to human genomic biomarkers, and 52 referred to microbial genomic biomarkers. Of the labels referring to human biomarkers, 43 (62%) pertained to polymorphisms in cytochrome P450 (CYP) enzyme metabolism, with CYP2D6 being most common. Of 36.1 million patients whose prescriptions were processed by a large pharmacy benefits manager in 2006, about 8.8 million (24.3%) received one or more drugs with human genomic biomarker information in the drug label. Conclusion. Nearly one fourth of all outpatients received one or more drugs that have pharmacogenomic information in the label for that drug. The incorporation and appropriate use of pharmacogenomic information in drug labels should be tested for its ability to improve drug use and safety in the United States.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review
Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., & Sadee, W. (2001) · JAMA · doi:10.1001/jama.286.18.2270 · Cited by 705
Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother
Koren, G., Cairns, J., Chitayat, D., Gaedigk, A., & Leeder, S. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69255-6 · Cited by 684
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9428-0 · Cited by 552
BORGES, S., DESTA, Z., LI, L., SKAAR, T., WARD, B., NGUYEN, A., JIN, Y., STORNIOLO, A., NIKOLOFF, D., & WU, L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.013 · Cited by 487
Mitchell, J. R., Thorgeirsson, U. P., Black, M., Timbrell, J. A., Snodgrass, W. R., Potter, W. Z., Jollow, D. J., & Keiser, H. R. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197518170 · Cited by 300
Personalized Medicine: Elusive Dream or Imminent Reality?
Lesko, L. J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100204 · Cited by 190
Self-citationThe Prospects for “Personalized Medicine” in Drug Development and Drug Therapy
Woodcock, J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100063 · Cited by 179
Guidance for Industry: Pharmacogenomic Data Submissions
(2004) · Biotechnology Law Report · doi:10.1089/073003104322838303 · Cited by 83
Zineh, I., Gerhard, T., Aquilante, C. L., Beitelshees, A. L., Beasley, B. N., & Hartzema, A. G. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500284 · Cited by 48
Pharmacogenetics, Pharmacogenomics and Personalized Medicine: Are We There Yet?
Davies, S. M. (2006) · Hematology · doi:10.1182/asheducation-2006.1.111 · Cited by 44
The Emerging Role of Pharmacogenomics in Biologics
Lacaná, E., Amur, S., Mummanneni, P., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100334 · Cited by 43
Self-citationZineh, I., Pebanco, G. D. O., Aquilante, C. L., et al. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g464 · Cited by 32
Cited by
The Path to Personalized Medicine
Hamburg, M. A., & Collins, F. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1006304 · Cited by 1,970
Charting a course for genomic medicine from base pairs to bedside
National Human Genome Research Institute, Green, E. D., & Guyer, M. S. (2011) · Nature · doi:10.1038/nature09764 · Cited by 902
Pulley, J. M., Denny, J. C., Peterson, J. F., Bernard, G. R., Vnencak-Jones, C. L., Ramirez, A. H., Delaney, J. T., Bowton, E., Brothers, K., Johnson, K., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.371 · Cited by 414
3D printed multi-compartment capsular devices for two-pulse oral drug delivery
Maroni, A., Melocchi, A., Parietti, F., Foppoli, A., Zema, L., & Gazzaniga, A. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.10.008 · Cited by 268
Primary care physicians' knowledge of and experience with pharmacogenetic testing
Haga, S., Burke, W., Ginsburg, G., Mills, R., & Agans, R. (2012) · Clinical Genetics · doi:10.1111/j.1399-0004.2012.01908.x · Cited by 253
Metadata
- Authors
- Frueh, F. W., Amur, S., Mummaneni, P., Epstein, R. S., Aubert, R. E., DeLuca, T. M., Verbrugge, R. R., Burckart, G. J., & Lesko, L. J.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2008-08
- Volume
- 28
- Issue
- 8
- Pages
- 992-998
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2123574746
- Cited by
- 307
- References
- 13
- FWCI
- 26.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.